The Latest Breaking News from Moderna

FDA panel backs first-of-its-kind flu vaccine using mRNA technology

A new kind of flu vaccine is moving a step closer to the U.S. market

AAP · Jun 18

FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Intense Scrutiny

FDA VRBPAC votes June 18 on Moderna's MFLUSIVA — the first mRNA flu vaccine. Phase 3 showed 26.6% RVE vs. standard dose; 47.9% vs. healthcare outcomes. PDUFA August 5, 2026.

Medical Daily · Jun 18

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

U.S. health advisers are debating a new kind of flu vaccine

AAP · Jun 18

Oxford University and Moderna launch trials of vaccine that could prevent cancer

The jab targets patients with Lynch syndrome, who are at high risk of colorectal and ovarian cancer

The Independent UK · Jun 8

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

Barchart · Jun 4

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access…

The Economic Times · Jun 2

Moderna and other groups get $60 million to develop Ebola vaccine

CEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will support Moderna, the University of Oxford, and the International AIDS Vaccine Initiative. The goal is to have trial-ready vaccines within months.

The Economic Times · Jun 2

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

MarketBeat · May 20

Immunovant Q4 Earnings Call Highlights

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

MarketBeat · May 20

Staged claims and Israeli hoaxes: Debunking viral conspiracy theories about hantavirus

Misinformation about hantavirus has run rampant on social media, with online users reviving viral COVID-19 theories to spread fake news about the outbreak.

Euronews · May 13